

BioPharma Quotes Tim Ehrlich in “Biotech IPOs heated up to start 2024. Will the surge last?”

Insights

March 5, 2024

Gunderson Dettmer Boston partner and co-chair of the firm’s Life Science practice group, Tim Ehrlich, is quoted in BioPharma’s article on the biotechnology sector’s notable resurgence in initial public offerings in 2024.

Tim spoke on how the biotech Metagenomi’s efforts to go public were being watched by industry observers as a test of whether IPOs were open to earlier-stage companies. “To really see momentum, we need to see an expansion of the opportunity for companies,’ he said, so startups nearing human testing also have a shot.”

Read the full article [here](#).

Related People



Timothy H. Ehrlich

THOMAS H. EMMETT
PARTNER
P +1 617 648 9399

Related Services

Life Sciences Licensing & Strategic Partnering

Featured Insights

CLIENT NEWS

BRIK Announces \$10M Series A Funding

FIRM NEWS

Gunderson Dettmer Leads 2025 PitchBook Global League Tables for Q1

CLIENT NEWS

Lux Capital and NewView Capital Invest in \$200M Series E of Stord

INSIGHTS

Client Insight: BE-10 Benchmark Survey of US Direct Investment Abroad

CLIENT NEWS

Granite Asia Leads \$20.5M Funding of VFlow

CLIENT NEWS

Gunderson Dettmer Client EPOS Acquired by Ant Financial

INSIGHTS

Chambers and Partners Global Practice Guide 2025: Venture Capital
(Singapore Chapter)

CLIENT NEWS

Insurtech Bestow Announces \$120M Series D and \$50M Credit Facility

CLIENT NEWS

Cart.com Raises \$50M Additional Financing

CLIENT NEWS

VMetrix Announces USD \$3 Million Series Seed Financing

CLIENT NEWS

Gunderson Dettmer Represented Hims & Hers Health, Inc. in Upsized \$1 Billion Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

CLIENT NEWS

Anduril Announces Acquisition of Klas to Advance Tactical Edge Computing and Communications